Ogura, Yuichiro https://orcid.org/0000-0003-0430-5330
Jaffe, Glenn J
Cheung, Chui Ming Gemmy https://orcid.org/0000-0003-3358-3516
Kokame, Gregg T https://orcid.org/0000-0001-7487-2205
Iida, Tomohiro
Takahashi, Kanji
Lee, Won Ki
Chang, Andrew A https://orcid.org/0000-0001-7555-1585
Monés, Jordi
D’Souza, Divya
Weissgerber, Georges
Gedif, Kinfemichael
Koh, Adrian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
https://doi.org/10.1136/bmjophth-2019-000398
Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER
https://doi.org/10.1136/bjo-2023-323577
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration
https://doi.org/10.1016/j.ophtha.2015.12.030
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
https://doi.org/10.1136/bjophthalmol-2021-319090
Funding for this research was provided by:
Novartis